SICURANZA ANNA

Anna
Sicuranza
Ricercatore Legge 240/10 - tempo determinato

Teaching activities

Completion accademic year: 2021/2022

Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2019/2020

Completion accademic year: 2020/2021

Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2018/2019

Completion accademic year: 2019/2020

Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2017/2018

Completion accademic year: 2018/2019

Research

Ultime pubblicazioni:

  • Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M.E., Miglino, M., et al. (2021). Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden. CANCERS, 13(1), 1-13. - view more
  • Caocci, G., Mulas, O., Capodanno, I., Bonifacio, M., Annunziata, M., Galimberti, S., et al. (2021). Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. ANNALS OF HEMATOLOGY. - view more
  • Bacchiarri, F., Sammartano, V., Santoni, A., Raspadori, D., Zappone, E., Defina, M., et al. (2021). First reported case of secondary mixed phenotype acute leukemia after multiple myeloma. AMERICAN JOURNAL OF BLOOD RESEARCH, 11(1), 123-131. - view more
  • Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., & Bocchia, M. (2021). The role of tumor-associated macrophages in hematologic malignancies. CANCERS, 13(14), 1-23 [10.3390/cancers13143597]. - view more
  • Vanni, F., Lopresti, L., Zurli, V., Kabanova, A., Cattaneo, F., Sicuranza, A., et al. (2021). A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis. PHARMACOLOGICAL RESEARCH, 174 [10.1016/j.phrs.2021.105965]. - view more